Compare Jones Lang LaSalle Inc (JLL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Novartis AG — how do they compare? Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 19.3× Jones Lang LaSalle Inc's market cap, and Novartis AG pays a 3.31% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Novartis AG for 82 Days on average.
| JLL | NVS | |
|---|---|---|
Market Cap | $13.95B | $268.57B |
Volume | 457,462 | 1,532,573 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $168.62 |
52-Week Low | $280.16 | $121.80 |
Typical Hold Time | 71 Days | 82 Days |
Enterprise Value | $16.71B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $303.14, up 2.18% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $26.12B in 2025 and improving profit margins. Analyst consensus remains bullish with a $450.50 price target, though technical indicators suggest near-term caution.
JLL presents a compelling value opportunity with attractive valuation ratios (P/E 14.54, P/S 0.53) and consistent earnings outperformance. Key risks include real estate market cyclicality and competitive pressures, but strong institutional support and strategic acquisitions support long-term growth prospects.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
